/

Empresas

Fu

No verificado

Fujirebio

Sobre qué escribimos

BiotecnologíaCienciaIndustriaSaludSanidad

12 Comunicados de prensa

Ver todos los comunicados de prensa

14/01/2026

Biotecnología

Sanidad

Salud

Farmacéutica

Mercado laboral

Notice Concerning Change of Representative Executive Officer

Fuente

Editor

1.00

0

23/06/2025

Ciencia

Finanzas

Asociaciones/Profesionales

Biotecnología

Salud

Mercado de valores

Industria

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries

Fuente

Editor

1.00

0

05/06/2025

Mercado laboral

Industria

Salud

VIH, SIDA y enfermedades autoinmunes

Ciencia

Farmacéutica

Biotecnología

Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research

Fuente

Editor

1.00

0

04/06/2025

Industria

Psiquiatría

Salud

Material médico sanitario

Biotecnología

Sanidad

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

Fuente

Editor

1.00

0

17/05/2025

Industria

Biotecnología

Salud

Material médico sanitario

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fuente

Editor

1.00

0

23/04/2025

Multimedia

Industria

Salud

VIH, SIDA y enfermedades autoinmunes

Ciencia

Farmacéutica

Biotecnología

Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis

Fuente

Editor

1.00

0

18/03/2025

Industria

Sanidad

Material médico sanitario

VIH, SIDA y enfermedades autoinmunes

Salud

Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy

Fuente

Editor

1.00

0

23/12/2024

Biotecnología

Industria

Sanidad

Salud

Oncología

Ciencia

Mercado laboral

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

Fuente

Editor

1.00

0

28/10/2024

ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

Fuente

Editor

1.00

0

25/09/2024

Industria

Higiene alimentaria

Salud

Sanidad

Farmacéutica

Biotecnología

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0